Literature DB >> 849993

Normal insulin binding to cultured fibroblasts from patients with lipoatrophic diabetes.

A L Rosenbloom, S Goldstein, C C Yip.   

Abstract

Confluent fibroblasts were assayed for insulin binding to determine whether there was an inherent abnormality in receptor function to explain the insulin resistance of lipoatrophic diabetes (LD). Cells from three patients and four controls were compared for confluent density, receptor saturation, specific and non-specific binding and the concentration of unlabelled hormone producing 50% competition for binding with labelled ligand. Cells from patients with LD did not differ significantly in any of these characteristics from the controls. These findings indicate that there is not a basic defect in insulin receptors of LD patients. A secondary disruption of binding, e.g. by a circulating factor, remains possible.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 849993     DOI: 10.1210/jcem-44-4-803

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Some aspects of the genetics and etiology of spontaneous diabetes mellitus.

Authors:  E Pimentel
Journal:  Acta Diabetol Lat       Date:  1979 Jul-Sep

2.  Glucocorticoid-induced insulin resistance: the importance of postbinding events in the regulation of insulin binding, action, and degradation in freshly isolated and primary cultures of rat hepatocytes.

Authors:  J F Caro; J M Amatruda
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

3.  Primary defect of insulin receptors in skin fibroblasts cultured from an infant with leprechaunism and insulin resistance.

Authors:  E E Schilling; M M Rechler; C Grunfeld; A M Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

4.  Insulin resistance in uremia. Characterization of insulin action, binding, and processing in isolated hepatocytes from chronic uremic rats.

Authors:  J M Kauffman; J F Caro
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.